Pfizer has moved a giant leap closer to getting the strongest warning of serious neuropsychiatric events removed from the labelling of its anti-smoking drug Chantix in the US.
European regulators have removed the black triangle warning from the label of Pfizer’s smoking cessation drug Champix, on the back of data from a post-marketing surveillance study backing its neuropsychiatric safety.